id,x_name,x_type,x_source,x_external_source_id,relation,y_name,y_type,y_source,y_external_source_id
397,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20
398,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20
399,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20
400,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Memory loss for recent events,Phenotypes,National Institute for Health and Care Excellence,es_20
401,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Difficulty learning new information,Phenotypes,National Institute for Health and Care Excellence,es_20
402,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Subtle language problems,Phenotypes,National Institute for Health and Care Excellence,es_20
403,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Significant memory loss,Phenotypes,National Institute for Health and Care Excellence,es_20
404,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Confusion in daily activities,Phenotypes,National Institute for Health and Care Excellence,es_20
405,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Behavioral changes,Phenotypes,National Institute for Health and Care Excellence,es_20
406,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Severe memory loss,Phenotypes,National Institute for Health and Care Excellence,es_20
407,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Complete dependence on others,Phenotypes,National Institute for Health and Care Excellence,es_20
408,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,Physical symptoms,Phenotypes,National Institute for Health and Care Excellence,es_20
409,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
410,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
411,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
412,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
413,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
414,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
415,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
416,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
417,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
418,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
419,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,EMC,es_14
420,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,EMC,es_14
421,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,EMC,es_14
422,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,EMC,es_14
423,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
424,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
425,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
426,Memantine Treatment renal impairment 3 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
427,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
428,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,High quality (Level A),Evidence,EMC,es_14
429,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
430,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Donepezil,drug,National Institute for Health and Care Excellence,es_20
431,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20
432,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Donepezil 5mg/day,Dosage,National Institute for Health and Care Excellence,es_20
433,Donepezil 5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,1 month,Duration,National Institute for Health and Care Excellence,es_20
434,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20
435,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Donepezil 10mg/day,Dosage,National Institute for Health and Care Excellence,es_20
436,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_POPULATION,increased if tolerated and necessary,Population,National Institute for Health and Care Excellence,es_20
437,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,Significant improvement in cognitive scores and daily activities,Effectiveness,National Institute for Health and Care Excellence,es_20
438,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20
439,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
440,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Galantamine,drug,National Institute for Health and Care Excellence,es_20
441,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20
442,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20
443,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,4 week,Duration,National Institute for Health and Care Excellence,es_20
444,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20
445,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Galantamine 16mg/day,Dosage,National Institute for Health and Care Excellence,es_20
446,Galantamine 16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,least 4 week,Duration,National Institute for Health and Care Excellence,es_20
447,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Galantamine Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20
448,Galantamine Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Galantamine 16-24mg/day,Dosage,National Institute for Health and Care Excellence,es_20
449,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20
450,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Galantamine,drug,National Institute for Health and Care Excellence,es_20
451,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20
452,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20
453,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,1 week,Duration,National Institute for Health and Care Excellence,es_20
454,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Galantamine Treatment moderate hepatic impairment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20
455,Galantamine Treatment moderate hepatic impairment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Galantamine 8-16mg/day,Dosage,National Institute for Health and Care Excellence,es_20
456,Galantamine 8-16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,4 week,Duration,National Institute for Health and Care Excellence,es_20
457,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,moderate hepatic impairment,Population,National Institute for Health and Care Excellence,es_20
458,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20
459,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20
460,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Rivastigmine 1.5-6.0 twice daily,Dosage,National Institute for Health and Care Excellence,es_20
461,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20
462,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20
463,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20
464,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Rivastigmine Patch 4.6mg/day,Dosage,National Institute for Health and Care Excellence,es_20
465,Rivastigmine Patch 4.6mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,4 week,Duration,National Institute for Health and Care Excellence,es_20
466,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20
467,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Rivastigmine Patch 9.5mg/day,Dosage,National Institute for Health and Care Excellence,es_20
468,Rivastigmine Patch 9.5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,6 week,Duration,National Institute for Health and Care Excellence,es_20
469,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,Rivastigmine Patch Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20
470,Rivastigmine Patch Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,Rivastigmine Patch 13.3mg/day,Dosage,National Institute for Health and Care Excellence,es_20
471,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20
472,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
473,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Memantine,drug,National Institute for Health and Care Excellence,es_20
474,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Memantine 5-20 mg/day,Dosage,National Institute for Health and Care Excellence,es_20
475,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20
476,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,National Institute for Health and Care Excellence,es_20
477,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20
478,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Memantine,drug,National Institute for Health and Care Excellence,es_20
479,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Memantine 10-20 mg/day,Dosage,National Institute for Health and Care Excellence,es_20
480,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20
481,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,eGFR is 3049 mL/minute/1.73 m簡,Population,National Institute for Health and Care Excellence,es_20
482,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20
483,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Memantine,drug,National Institute for Health and Care Excellence,es_20
484,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Memantine 10 mg/day,Dosage,National Institute for Health and Care Excellence,es_20
485,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20
486,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,eGFR is 5 - 29 mL/minute/1.73 m簡,Population,National Institute for Health and Care Excellence,es_20
487,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
488,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Haloperidol,drug,National Institute for Health and Care Excellence,es_20
489,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Haloperidol 0.5-5 mg/day,Dosage,National Institute for Health and Care Excellence,es_20
490,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,no more than 6 weeks,Duration,National Institute for Health and Care Excellence,es_20
491,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20
492,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,Risperidone,drug,National Institute for Health and Care Excellence,es_20
493,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,Risperidone 0.5-5 mg/day,Dosage,National Institute for Health and Care Excellence,es_20
494,Risperidone 0.5-5 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,no more than 6 weeks,Duration,National Institute for Health and Care Excellence,es_20
495,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20
496,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20
497,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Anorexia,SideEffect,National Institute for Health and Care Excellence,es_20
498,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,National Institute for Health and Care Excellence,es_20
499,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Muscle cramps,SideEffect,National Institute for Health and Care Excellence,es_20
500,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20
501,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Headache,SideEffect,National Institute for Health and Care Excellence,es_20
502,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20
503,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abnormal dreams,SideEffect,National Institute for Health and Care Excellence,es_20
504,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20
505,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Agitation,SideEffect,National Institute for Health and Care Excellence,es_20
506,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Aggression,SideEffect,National Institute for Health and Care Excellence,es_20
507,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Urinary incontinence,SideEffect,National Institute for Health and Care Excellence,es_20
508,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Rash,SideEffect,National Institute for Health and Care Excellence,es_20
509,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Pruritus,SideEffect,National Institute for Health and Care Excellence,es_20
510,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20
511,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sinoatrial block,SideEffect,National Institute for Health and Care Excellence,es_20
512,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Atrioventricular (AV) block,SideEffect,National Institute for Health and Care Excellence,es_20
513,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Liver dysfunction (including hepatitis),SideEffect,National Institute for Health and Care Excellence,es_20
514,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20
515,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20
516,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Insomnia,SideEffect,National Institute for Health and Care Excellence,es_20
517,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20
518,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20
519,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abdominal pain,SideEffect,National Institute for Health and Care Excellence,es_20
520,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Diarrhoea,SideEffect,National Institute for Health and Care Excellence,es_20
521,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dyspepsia,SideEffect,National Institute for Health and Care Excellence,es_20
522,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Decreased appetite,SideEffect,National Institute for Health and Care Excellence,es_20
523,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Weight loss ,SideEffect,National Institute for Health and Care Excellence,es_20
524,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Bradycardia,SideEffect,National Institute for Health and Care Excellence,es_20
525,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20
526,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20
527,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20
528,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Depression,SideEffect,National Institute for Health and Care Excellence,es_20
529,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20
530,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Tremor,SideEffect,National Institute for Health and Care Excellence,es_20
531,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Headache,SideEffect,National Institute for Health and Care Excellence,es_20
532,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20
533,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Malaise,SideEffect,National Institute for Health and Care Excellence,es_20
534,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Muscle spasm,SideEffect,National Institute for Health and Care Excellence,es_20
535,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Retching,SideEffect,National Institute for Health and Care Excellence,es_20
536,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dehydration,SideEffect,National Institute for Health and Care Excellence,es_20
537,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypotension,SideEffect,National Institute for Health and Care Excellence,es_20
538,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Flushing,SideEffect,National Institute for Health and Care Excellence,es_20
539,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Palpitation,SideEffect,National Institute for Health and Care Excellence,es_20
540,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Arrhythmias,SideEffect,National Institute for Health and Care Excellence,es_20
541,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,First-degree AV block,SideEffect,National Institute for Health and Care Excellence,es_20
542,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Taste disturbance,SideEffect,National Institute for Health and Care Excellence,es_20
543,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Paraesthesia,SideEffect,National Institute for Health and Care Excellence,es_20
544,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20
545,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypersomnia,SideEffect,National Institute for Health and Care Excellence,es_20
546,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Muscular weakness,SideEffect,National Institute for Health and Care Excellence,es_20
547,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Blurred vision,SideEffect,National Institute for Health and Care Excellence,es_20
548,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Tinnitus,SideEffect,National Institute for Health and Care Excellence,es_20
549,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sweating,SideEffect,National Institute for Health and Care Excellence,es_20
550,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Exacerbation of Parkinson's disease,SideEffect,National Institute for Health and Care Excellence,es_20
551,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hepatitis,SideEffect,National Institute for Health and Care Excellence,es_20
552,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Serious skin reactions,SideEffect,National Institute for Health and Care Excellence,es_20
553,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20
554,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20
555,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Diarrhoea,SideEffect,National Institute for Health and Care Excellence,es_20
556,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dyspepsia,SideEffect,National Institute for Health and Care Excellence,es_20
557,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Anorexia,SideEffect,National Institute for Health and Care Excellence,es_20
558,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Weight loss,SideEffect,National Institute for Health and Care Excellence,es_20
559,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abdominal pain,SideEffect,National Institute for Health and Care Excellence,es_20
560,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Bradycardia,SideEffect,National Institute for Health and Care Excellence,es_20
561,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20
562,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Headache,SideEffect,National Institute for Health and Care Excellence,es_20
563,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Drowsiness,SideEffect,National Institute for Health and Care Excellence,es_20
564,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Gait abnormalities,SideEffect,National Institute for Health and Care Excellence,es_20
565,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Fall,SideEffect,National Institute for Health and Care Excellence,es_20
566,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Malaise,SideEffect,National Institute for Health and Care Excellence,es_20
567,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Agitation,SideEffect,National Institute for Health and Care Excellence,es_20
568,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Anxiety,SideEffect,National Institute for Health and Care Excellence,es_20
569,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Tremor,SideEffect,National Institute for Health and Care Excellence,es_20
570,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Confusion,SideEffect,National Institute for Health and Care Excellence,es_20
571,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Insomnia,SideEffect,National Institute for Health and Care Excellence,es_20
572,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Parkinsonism,SideEffect,National Institute for Health and Care Excellence,es_20
573,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20
574,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Skin reactions,SideEffect,National Institute for Health and Care Excellence,es_20
575,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Urinary tract infection,SideEffect,National Institute for Health and Care Excellence,es_20
576,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Urinary incontinence,SideEffect,National Institute for Health and Care Excellence,es_20
577,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sweating,SideEffect,National Institute for Health and Care Excellence,es_20
578,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Atrial fibrillation,SideEffect,National Institute for Health and Care Excellence,es_20
579,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,AV block,SideEffect,National Institute for Health and Care Excellence,es_20
580,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Depression,SideEffect,National Institute for Health and Care Excellence,es_20
581,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Aggression,SideEffect,National Institute for Health and Care Excellence,es_20
582,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20
583,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Gastric and duodenal ulceration,SideEffect,National Institute for Health and Care Excellence,es_20
584,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Pancreatitis,SideEffect,National Institute for Health and Care Excellence,es_20
585,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Angina,SideEffect,National Institute for Health and Care Excellence,es_20
586,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20
587,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dehydration,SideEffect,National Institute for Health and Care Excellence,es_20
588,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20
589,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hepatitis,SideEffect,National Institute for Health and Care Excellence,es_20
590,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Restlessness,SideEffect,National Institute for Health and Care Excellence,es_20
591,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sick sinus syndrome,SideEffect,National Institute for Health and Care Excellence,es_20
592,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Tachycardia,SideEffect,National Institute for Health and Care Excellence,es_20
593,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20
594,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Constipation,SideEffect,National Institute for Health and Care Excellence,es_20
595,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20
596,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dyspnoea,SideEffect,National Institute for Health and Care Excellence,es_20
597,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Headache,SideEffect,National Institute for Health and Care Excellence,es_20
598,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20
599,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Impaired balance,SideEffect,National Institute for Health and Care Excellence,es_20
600,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Drowsiness,SideEffect,National Institute for Health and Care Excellence,es_20
601,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20
602,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Thrombosis,SideEffect,National Institute for Health and Care Excellence,es_20
603,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Heart failure,SideEffect,National Institute for Health and Care Excellence,es_20
604,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Confusion,SideEffect,National Institute for Health and Care Excellence,es_20
605,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20
606,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20
607,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abnormal gait,SideEffect,National Institute for Health and Care Excellence,es_20
608,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20
609,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Pancreatitis,SideEffect,National Institute for Health and Care Excellence,es_20
610,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Psychosis,SideEffect,National Institute for Health and Care Excellence,es_20
611,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Depression,SideEffect,National Institute for Health and Care Excellence,es_20
612,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Suicidal ideation,SideEffect,National Institute for Health and Care Excellence,es_20
613,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20
614,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Weight gain,SideEffect,National Institute for Health and Care Excellence,es_20
615,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dyslipidaemia,SideEffect,National Institute for Health and Care Excellence,es_20
616,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hyperprolactinaemia,SideEffect,National Institute for Health and Care Excellence,es_20
617,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sedation,SideEffect,National Institute for Health and Care Excellence,es_20
618,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sleep apnoea syndrome,SideEffect,National Institute for Health and Care Excellence,es_20
619,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Anticholinergic effects,SideEffect,National Institute for Health and Care Excellence,es_20
620,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Postural hypotension,SideEffect,National Institute for Health and Care Excellence,es_20
621,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20
622,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Reduced seizure threshold,SideEffect,National Institute for Health and Care Excellence,es_20
623,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Impaired glucose tolerance,SideEffect,National Institute for Health and Care Excellence,es_20
624,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",SideEffect,National Institute for Health and Care Excellence,es_20
625,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,QT interval prolongation,SideEffect,National Institute for Health and Care Excellence,es_20
626,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Stroke risk,SideEffect,National Institute for Health and Care Excellence,es_20
627,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Venous thromboembolism (VTE),SideEffect,National Institute for Health and Care Excellence,es_20
628,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20
629,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Pneumonia,SideEffect,National Institute for Health and Care Excellence,es_20
630,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Neutropenia,SideEffect,National Institute for Health and Care Excellence,es_20
631,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abnormal liver function tests (LFTs),SideEffect,National Institute for Health and Care Excellence,es_20
632,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Photosensitivity,SideEffect,National Institute for Health and Care Excellence,es_20
633,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Skin and subcutaneous tissue disorders,SideEffect,National Institute for Health and Care Excellence,es_20
634,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Diplopia,SideEffect,National Institute for Health and Care Excellence,es_20
635,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Misuse and abuse,SideEffect,National Institute for Health and Care Excellence,es_20
636,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Restless legs syndrome,SideEffect,National Institute for Health and Care Excellence,es_20
637,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20
638,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Weight gain,SideEffect,National Institute for Health and Care Excellence,es_20
639,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Dyslipidaemia,SideEffect,National Institute for Health and Care Excellence,es_20
640,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hyperprolactinaemia,SideEffect,National Institute for Health and Care Excellence,es_20
641,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sedation,SideEffect,National Institute for Health and Care Excellence,es_20
642,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Sleep apnoea syndrome,SideEffect,National Institute for Health and Care Excellence,es_20
643,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Anticholinergic effects,SideEffect,National Institute for Health and Care Excellence,es_20
644,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Postural hypotension,SideEffect,National Institute for Health and Care Excellence,es_20
645,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20
646,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Reduced seizure threshold,SideEffect,National Institute for Health and Care Excellence,es_20
647,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Impaired glucose tolerance,SideEffect,National Institute for Health and Care Excellence,es_20
648,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",SideEffect,National Institute for Health and Care Excellence,es_20
649,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,QT interval prolongation,SideEffect,National Institute for Health and Care Excellence,es_20
650,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Stroke risk,SideEffect,National Institute for Health and Care Excellence,es_20
651,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Venous thromboembolism (VTE),SideEffect,National Institute for Health and Care Excellence,es_20
652,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20
653,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Pneumonia,SideEffect,National Institute for Health and Care Excellence,es_20
654,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Neutropenia,SideEffect,National Institute for Health and Care Excellence,es_20
655,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Abnormal liver function tests (LFTs),SideEffect,National Institute for Health and Care Excellence,es_20
656,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Photosensitivity,SideEffect,National Institute for Health and Care Excellence,es_20
657,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Skin and subcutaneous tissue disorders,SideEffect,National Institute for Health and Care Excellence,es_20
658,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Diplopia,SideEffect,National Institute for Health and Care Excellence,es_20
659,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Misuse and abuse,SideEffect,National Institute for Health and Care Excellence,es_20
660,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,Restless legs syndrome,SideEffect,National Institute for Health and Care Excellence,es_20
661,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20
662,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20
663,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20
664,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20
665,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20
666,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20
667,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20
668,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20
669,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,Improves memory attention and social interaction,Effectiveness,National Institute for Health and Care Excellence,es_20
670,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,Helps maintain long-term memory improves mood,Effectiveness,National Institute for Health and Care Excellence,es_20
671,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,Reduces anxiety and agitation improves daily functioning,Effectiveness,National Institute for Health and Care Excellence,es_20
672,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,Improves mood reduces agitation provides positive emotions,Effectiveness,National Institute for Health and Care Excellence,es_20
673,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe cardiac arrhythmia,Phenotypes,National Institute for Health and Care Excellence,es_20
674,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20
675,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",Phenotypes,National Institute for Health and Care Excellence,es_20
676,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"History of bradycardia, heart block, recurrent unexplained syncope.",Phenotypes,National Institute for Health and Care Excellence,es_20
677,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Concurrent treatment with drugs that reduce heart rate.,Phenotypes,National Institute for Health and Care Excellence,es_20
678,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Sick sinus syndrome or other supraventricular conduction abnormalities.,Phenotypes,National Institute for Health and Care Excellence,es_20
679,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Susceptibility to peptic ulcers including concurrent nonsteroidalanti inflammatory(NSAID) use.,Phenotypes,National Institute for Health and Care Excellence,es_20
680,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Asthma and chronic obstructive pulmonary disease (COPD).,Phenotypes,National Institute for Health and Care Excellence,es_20
681,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20
682,Donepezil,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Concomitant antipsychotic treatment  increased risk of neuroleptic malignant syndrome (NMS).,Phenotypes,National Institute for Health and Care Excellence,es_20
683,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Concomitant antipsychotic treatment  increased risk of neuroleptic malignant syndrome (NMS).,Phenotypes,National Institute for Health and Care Excellence,es_20
684,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hypersensitivity to galantamine or to any of the excipients.,Phenotypes,National Institute for Health and Care Excellence,es_20
685,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m簡).,Phenotypes,National Institute for Health and Care Excellence,es_20
686,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe hepatic impairment (Child-Pugh score greater than 9).,Phenotypes,National Institute for Health and Care Excellence,es_20
687,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,People who have both significant renal and hepatic dysfunction.,Phenotypes,National Institute for Health and Care Excellence,es_20
688,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Urinary outflow obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20
689,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Gastrointestinal obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20
690,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,During recovery from bladder or gastrointestinal surgery.,Phenotypes,National Institute for Health and Care Excellence,es_20
691,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20
692,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Renal and hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20
693,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",Phenotypes,National Institute for Health and Care Excellence,es_20
694,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,QTc interval prolongation or taking drugs that prolong the QTc interval.,Phenotypes,National Institute for Health and Care Excellence,es_20
695,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,Phenotypes,National Institute for Health and Care Excellence,es_20
696,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",Phenotypes,National Institute for Health and Care Excellence,es_20
697,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"History of severe asthma, COPD, or pulmonary infection.",Phenotypes,National Institute for Health and Care Excellence,es_20
698,Galantamine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20
699,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",Phenotypes,National Institute for Health and Care Excellence,es_20
700,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,Phenotypes,National Institute for Health and Care Excellence,es_20
701,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20
702,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20
703,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Renal impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20
704,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Gastric or duodenal ulcers (or susceptibility to ulcers).,Phenotypes,National Institute for Health and Care Excellence,es_20
705,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Sick sinus syndrome or conduction abnormalities.,Phenotypes,National Institute for Health and Care Excellence,es_20
706,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of asthma or COPD.,Phenotypes,National Institute for Health and Care Excellence,es_20
707,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20
708,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Bladder outflow obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20
709,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Pre-existing, or a family history of, QT interval prolongation.",Phenotypes,National Institute for Health and Care Excellence,es_20
710,Rivastigmine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Higher risk of developing torsade de pointes,Phenotypes,National Institute for Health and Care Excellence,es_20
711,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",Phenotypes,National Institute for Health and Care Excellence,es_20
712,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20
713,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe renal impairment  memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m簡.,Phenotypes,National Institute for Health and Care Excellence,es_20
714,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of convulsions or predisposing factors for epilepsy.,Phenotypes,National Institute for Health and Care Excellence,es_20
715,Memantine,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe renal impairment,Phenotypes,National Institute for Health and Care Excellence,es_20
716,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Central nervous system depression, comatose states.",Phenotypes,National Institute for Health and Care Excellence,es_20
717,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",Phenotypes,National Institute for Health and Care Excellence,es_20
718,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"prolongation, concurrent use with drugs that prolong the QT interval, history of",Phenotypes,National Institute for Health and Care Excellence,es_20
719,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",Phenotypes,National Institute for Health and Care Excellence,es_20
720,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Uncorrected hypokalaemia.,Phenotypes,National Institute for Health and Care Excellence,es_20
721,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Progressive supranuclear palsy.,Phenotypes,National Institute for Health and Care Excellence,es_20
722,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Dementia with Lewy bodies.,Phenotypes,National Institute for Health and Care Excellence,es_20
723,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Parkinson's disease.,Phenotypes,National Institute for Health and Care Excellence,es_20
724,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Blood dyscrasias.,Phenotypes,National Institute for Health and Care Excellence,es_20
725,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Cardiovascular disease  an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",Phenotypes,National Institute for Health and Care Excellence,es_20
726,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Conditions predisposing to seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20
727,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Depression.,Phenotypes,National Institute for Health and Care Excellence,es_20
728,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Diabetes (may raise blood glucose).,Phenotypes,National Institute for Health and Care Excellence,es_20
729,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Epilepsy.,Phenotypes,National Institute for Health and Care Excellence,es_20
730,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of jaundice.,Phenotypes,National Institute for Health and Care Excellence,es_20
731,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Myasthenia gravis.,Phenotypes,National Institute for Health and Care Excellence,es_20
732,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Parkinson宎s disease (may be exacerbated).,Phenotypes,National Institute for Health and Care Excellence,es_20
733,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Photosensitization (may occur with higher dosages).,Phenotypes,National Institute for Health and Care Excellence,es_20
734,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Prostatic hypertrophy.,Phenotypes,National Institute for Health and Care Excellence,es_20
735,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe respiratory disease.,Phenotypes,National Institute for Health and Care Excellence,es_20
736,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Susceptibility to angle-closure glaucoma,Phenotypes,National Institute for Health and Care Excellence,es_20
737,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Bradycardia.,Phenotypes,National Institute for Health and Care Excellence,es_20
738,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Uncorrected electrolyte disturbances.,Phenotypes,National Institute for Health and Care Excellence,es_20
739,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Family history of QTc-interval prolongation.,Phenotypes,National Institute for Health and Care Excellence,es_20
740,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of heavy alcohol exposure.,Phenotypes,National Institute for Health and Care Excellence,es_20
741,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hyperthyroidism.,Phenotypes,National Institute for Health and Care Excellence,es_20
742,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hypotension (including orthostatic hypotension).,Phenotypes,National Institute for Health and Care Excellence,es_20
743,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Prolactin-dependent tumours.,Phenotypes,National Institute for Health and Care Excellence,es_20
744,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Prolactinaemia.,Phenotypes,National Institute for Health and Care Excellence,es_20
745,Haloperidol,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Risk factors for stroke.,Phenotypes,National Institute for Health and Care Excellence,es_20
746,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Hypersensitivity to risperidone or to any of the excipients.,Phenotypes,National Institute for Health and Care Excellence,es_20
747,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Acute porphyrias.,Phenotypes,National Institute for Health and Care Excellence,es_20
748,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Cataract surgery (risk of intra-operative floppy iris syndrome).,Phenotypes,National Institute for Health and Care Excellence,es_20
749,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Dehydration.,Phenotypes,National Institute for Health and Care Excellence,es_20
750,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Dementia with Lewy bodies.,Phenotypes,National Institute for Health and Care Excellence,es_20
751,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Prolactin-dependent tumours.,Phenotypes,National Institute for Health and Care Excellence,es_20
752,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Blood dyscrasias.,Phenotypes,National Institute for Health and Care Excellence,es_20
753,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,"Cardiovascular disease  an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",Phenotypes,National Institute for Health and Care Excellence,es_20
754,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Conditions predisposing to seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20
755,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Depression.,Phenotypes,National Institute for Health and Care Excellence,es_20
756,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Diabetes (may raise blood glucose).,Phenotypes,National Institute for Health and Care Excellence,es_20
757,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Epilepsy.,Phenotypes,National Institute for Health and Care Excellence,es_20
758,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,History of jaundice.,Phenotypes,National Institute for Health and Care Excellence,es_20
759,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Myasthenia gravis.,Phenotypes,National Institute for Health and Care Excellence,es_20
760,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Parkinson宎s disease (may be exacerbated).,Phenotypes,National Institute for Health and Care Excellence,es_20
761,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Photosensitization (may occur with higher dosages).,Phenotypes,National Institute for Health and Care Excellence,es_20
762,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Prostatic hypertrophy.,Phenotypes,National Institute for Health and Care Excellence,es_20
763,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Severe respiratory disease.,Phenotypes,National Institute for Health and Care Excellence,es_20
764,Risperidone,drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,Susceptibility to angle-closure glaucoma,Phenotypes,National Institute for Health and Care Excellence,es_20
765,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,MONITORING_TREATMENT,Weight monthly,Monitoring,National Institute for Health and Care Excellence,es_20
766,Alzheimer disease,disease,成功大學,es_19,DISEASES_STAGE,,Stage,成功大學,es_19
767,Alzheimer disease,disease,成功大學,es_19,DISEASES_STAGE,銝剜,Stage,成功大學,es_19
768,Alzheimer disease,disease,成功大學,es_19,DISEASES_STAGE,,Stage,成功大學,es_19
769,Alzheimer disease,disease,成功大學,es_19,DISEASES_TREATMENT,Donepezil Treatment (之),Treatment,成功大學,es_19
770,Donepezil Treatment (之),Treatment,成功大學,es_19,DRUG_TREATMENT,Donepezil,drug,成功大學,es_19
771,Donepezil Treatment (之),Treatment,成功大學,es_19,TREATMENT_STEP,Donepezil Treatment (之) (1),Step,成功大學,es_19
772,Donepezil Treatment (之) (1),Step,成功大學,es_19,STEP_DOSAGE,Donepezil 5 mg/day,Dosage,成功大學,es_19
773,Donepezil 5mg/day,Dosage,成功大學,es_19,DOSAGE_DURATION,4-6 week,Duration,成功大學,es_19
774,Donepezil Treatment (之) (1),Step,成功大學,es_19,STEP_STEP,Donepezil Treatment (之) (2),Step,成功大學,es_19
775,Donepezil Treatment (之) (2),Step,成功大學,es_19,STEP_DOSAGE,Donepezil 5-10 mg/day,Dosage,成功大學,es_19
776,Alzheimer disease,disease,成功大學,es_19,DISEASES_TREATMENT,Rivastigmine Treatment (NICE),Treatment,成功大學,es_19
777,Rivastigmine Treatment (之),Treatment,成功大學,es_19,DRUG_TREATMENT,Rivastigmine,drug,成功大學,es_19
778,Rivastigmine Treatment (之),Treatment,成功大學,es_19,TREATMENT_DOSAGE,Rivastigmine 1.5-6mg/day*2,Dosage,成功大學,es_19
779,Alzheimer disease,disease,成功大學,es_19,DISEASES_TREATMENT,Galantamine  Treatment (NICE),Treatment,成功大學,es_19
780,Galantamine Treatment (之),Treatment,成功大學,es_19,DRUG_TREATMENT,Galantamine,drug,成功大學,es_19
781,Galantamine Treatment (之),Treatment,成功大學,es_19,TREATMENT_STEP,Galantamine Treatment (之) (1),Step,成功大學,es_19
782,Galantamine Treatment (之) (1),Step,成功大學,es_19,STEP_DOSAGE,Galantamine 4mg/day*2,Dosage,成功大學,es_19
783,Galantamine Treatment (之) (1),Step,成功大學,es_19,STEP_STEP,Galantamine Treatment (之) (2),Step,成功大學,es_19
784,Galantamine Treatment (之) (2),Step,成功大學,es_19,STEP_DOSAGE,Galantamine 16-24mg/day,Dosage,成功大學,es_19
785,Alzheimer disease,disease,成功大學,es_19,DISEASES_TREATMENT,Memantine Treatment (NICE),Treatment,成功大學,es_19
786,Memantine Treatment (之),Treatment,成功大學,es_19,DRUG_TREATMENT,Memantine,drug,成功大學,es_19
787,Memantine Treatment (之),Treatment,成功大學,es_19,TREATMENT_DOSAGE,Memantine 5-20mg/day,Dosage,成功大學,es_19
788,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Nausea,SideEffect,成功大學,es_19
789,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,成功大學,es_19
790,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Insomnia,SideEffect,成功大學,es_19
791,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Vomiting,SideEffect,成功大學,es_19
792,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Muscle cramps,SideEffect,成功大學,es_19
793,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Fatigue,SideEffect,成功大學,es_19
794,Donepezil,drug,成功大學,es_19,DRUG_SIDE_EFFECT,decreased appetite,SideEffect,成功大學,es_19
795,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Headache,SideEffect,成功大學,es_19
796,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dizziness,SideEffect,成功大學,es_19
797,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Anxiety,SideEffect,成功大學,es_19
798,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Nausea,SideEffect,成功大學,es_19
799,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,成功大學,es_19
800,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Insomnia,SideEffect,成功大學,es_19
801,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Vomiting,SideEffect,成功大學,es_19
802,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Depressed,SideEffect,成功大學,es_19
803,Rivastigmine patch,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dyspepsia,SideEffect,成功大學,es_19
804,Rivastigmine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Nausea,SideEffect,成功大學,es_19
805,Rivastigmine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dizziness,SideEffect,成功大學,es_19
806,Rivastigmine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,成功大學,es_19
807,Rivastigmine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Anorexia,SideEffect,成功大學,es_19
808,Rivastigmine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Vomiting,SideEffect,成功大學,es_19
809,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Nausea,SideEffect,成功大學,es_19
810,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dizziness,SideEffect,成功大學,es_19
811,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,成功大學,es_19
812,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Anorexia,SideEffect,成功大學,es_19
813,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Vomiting,SideEffect,成功大學,es_19
814,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Drowsiness,SideEffect,成功大學,es_19
815,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Anorexia,SideEffect,成功大學,es_19
816,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dyspepsia,SideEffect,成功大學,es_19
817,Galantamine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Weight lose,SideEffect,成功大學,es_19
818,Memantine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Headache,SideEffect,成功大學,es_19
819,Memantine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Dizziness,SideEffect,成功大學,es_19
820,Memantine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Drowsiness,SideEffect,成功大學,es_19
821,Memantine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Vomiting,SideEffect,成功大學,es_19
822,Memantine,drug,成功大學,es_19,DRUG_SIDE_EFFECT,Hallucination,SideEffect,成功大學,es_19
823,Memantine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Myalgia,SideEffect,Ministry of Health Malaysia,es_18
824,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18
825,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18
826,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18
827,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18
828,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18
829,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18
830,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18
831,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18
832,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",Phenotypes,Ministry of Health Malaysia,es_18
833,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18
834,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,Fully dependent,Phenotypes,Ministry of Health Malaysia,es_18
835,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,Fully dependent,Phenotypes,Ministry of Health Malaysia,es_18
836,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
837,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
838,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
839,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
840,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
841,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
842,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
843,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
844,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
845,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
846,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
847,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
848,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
849,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
850,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
851,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
852,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
853,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
854,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
855,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,Memantine Treatment (MaHTAS),Treatment,Cochrane Library,es_10
856,Donepezil Treatment  (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,Cochrane Library,es_10
857,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,Cochrane Library,es_10
858,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,Cochrane Library,es_10
859,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,Cochrane Library,es_10
860,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Moderate to Low quality,Evidence,Cochrane Library,es_10
861,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
862,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,Donepezil,drug,Ministry of Health Malaysia,es_18
863,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,Donepezil 10 mg/day,Dosage,Ministry of Health Malaysia,es_18
864,Donepezil 10 mg/day,Dosage,Ministry of Health Malaysia,es_18,DOSAGE_DURATION,12-24 week,Duration,Ministry of Health Malaysia,es_18
865,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18
866,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
867,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,Rivastigmine,drug,Ministry of Health Malaysia,es_18
868,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,Rivastigmine 6 - 12 mg/day*2,Dosage,Ministry of Health Malaysia,es_18
869,Rivastigmine 6 - 12 mg/day*2,Dosage,Ministry of Health Malaysia,es_18,DOSAGE_DURATION,26 week,Duration,Ministry of Health Malaysia,es_18
870,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 0-26),Population,Ministry of Health Malaysia,es_18
871,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18
872,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,Rivastigmine,drug,Ministry of Health Malaysia,es_18
873,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,Rivastigmine,Dosage,Ministry of Health Malaysia,es_18
874,Rivastigmine Patch 9.5 mg/day,Dosage,Ministry of Health Malaysia,es_18,DOSAGE_DURATION,Rivastigmine,Duration,Ministry of Health Malaysia,es_18
875,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,Rivastigmine,Population,Ministry of Health Malaysia,es_18
876,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,Rivastigmine,Treatment,Ministry of Health Malaysia,es_18
877,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,Rivastigmine,drug,Ministry of Health Malaysia,es_18
878,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,Rivastigmine,Dosage,Ministry of Health Malaysia,es_18
879,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DOSAGE_DURATION,Rivastigmine,Duration,Ministry of Health Malaysia,es_18
880,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,Rivastigmine,Population,Ministry of Health Malaysia,es_18
881,Alzheimer disease,disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,Rivastigmine,Treatment,Ministry of Health Malaysia,es_18
882,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,Rivastigmine,drug,Ministry of Health Malaysia,es_18
883,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,Rivastigmine,Population,Ministry of Health Malaysia,es_18
884,Donepezil,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
885,Donepezil,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
886,Donepezil,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
887,Rivastigmine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
888,Rivastigmine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
889,Rivastigmine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
890,Rivastigmine Patch,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
891,Rivastigmine Patch,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
892,Rivastigmine Patch,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
893,Memantine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
894,Memantine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
895,Memantine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
896,Memantine,drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,Ministry of Health Malaysia,es_18
897,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,Rivastigmine,Therapy,Ministry of Health Malaysia,es_18
898,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,Rivastigmine,Therapy,Ministry of Health Malaysia,es_18
899,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,Rivastigmine,Therapy,Ministry of Health Malaysia,es_18
900,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,Rivastigmine,Therapy,Ministry of Health Malaysia,es_18
901,Exercise,Therapy,Ministry of Health Malaysia,es_18,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,Ministry of Health Malaysia,es_18
902,Diet and supplement,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
903,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
904,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
905,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
906,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
907,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,Cochrane Library,es_10
908,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
909,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
910,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
911,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
912,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,Cochrane Library,es_10
913,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
914,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
915,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
916,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
917,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
918,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,Rivastigmine,Treatment,Cochrane Library,es_10
919,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_11
920,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_11
921,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_12
922,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_12
923,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_7
924,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cochrane Library,es_7
925,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,JAMA,es_16
926,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,American Academy of Family Physicians,es_1
927,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
928,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
929,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
930,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
931,Donepezil 5mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
932,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
933,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
934,Donepezil 10 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
935,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
936,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
937,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
938,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
939,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
940,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
941,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
942,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
943,Rivastigmine 1.5 mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
944,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
945,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
946,Rivastigmine 3 mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
947,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
948,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
949,Rivastigmine 4.5 mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
950,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
951,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
952,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
953,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
954,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
955,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
956,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
957,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
958,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
959,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
960,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
961,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
962,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
963,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
964,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
965,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
966,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
967,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
968,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
969,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
970,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
971,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
972,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
973,Galantamine 8 mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
974,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
975,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
976,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
977,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
978,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
979,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
980,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
981,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
982,Galantamine 8 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
983,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
984,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
985,Galantamine 8 mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
986,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
987,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
988,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
989,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
990,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
991,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
992,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
993,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
994,Memantine 5mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
995,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
996,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
997,Memantine 5mg/day*2,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
998,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
999,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1000,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1001,Memantine 10mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1002,Memantine 5mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1003,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1004,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1005,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1006,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
1007,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
1008,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
1009,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1010,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1011,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1012,Memantine 7 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1013,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1014,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1015,Memantine 14 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1016,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1017,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1018,Memantine 14 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1019,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1020,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1021,Memantine 21 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1022,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1023,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1024,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1025,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
1026,Alzheimer disease,disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,Rivastigmine,Treatment,American Academy of Family Physicians,es_1
1027,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
1028,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
1029,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,Rivastigmine,drug,American Academy of Family Physicians,es_1
1030,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1031,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1032,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1033,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1034,Memantine 7 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1035,Donepezil 10mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1036,"Vitamin E 1,000IU/day*2",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1037,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1038,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1039,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1040,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1041,Memantine 14 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1042,Donepezil 10mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1043,"Vitamin E 1,000IU/day*2",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1044,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1045,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1046,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1047,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1048,Memantine 14 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1049,Donepezil 10mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1050,"Vitamin E 1,000IU/day*2",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1051,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1052,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1053,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1054,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1055,Memantine 21 mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1056,Donepezil 10mg/day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1057,"Vitamin E 1,000IU/day*2",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,Rivastigmine,Duration,American Academy of Family Physicians,es_1
1058,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_STEP,Rivastigmine,Step,American Academy of Family Physicians,es_1
1059,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1060,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1061,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,Rivastigmine,Dosage,American Academy of Family Physicians,es_1
1062,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1063,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,Rivastigmine,Population,American Academy of Family Physicians,es_1
1064,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1065,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1066,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1067,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1068,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1069,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1070,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1071,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1072,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1073,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1074,Donepezil,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1075,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1076,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1077,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1078,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1079,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1080,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1081,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1082,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1083,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1084,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1085,Rivastigmine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1086,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1087,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1088,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1089,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1090,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1091,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1092,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1093,Galantamine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1094,Memantine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1095,Memantine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1096,Memantine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1097,Memantine,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1098,Vitamin E,drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,American Academy of Family Physicians,es_1
1099,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1100,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1101,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1102,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1103,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1104,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1105,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1106,Alzheimer disease,disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,Rivastigmine,Therapy,National Institute for Health and Care Excellence,es_20
1107,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1108,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1109,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1110,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1111,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1112,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1113,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1114,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,Rivastigmine,Therapy,American Academy of Family Physicians,es_1
1115,Enjoyable leisure activities,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1116,Mental stimulation programs,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1117,Occupational therapy training in coping strategies and cognitive aides,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1118,Structured physical exercise programs,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,American Academy of Family Physicians,es_1
1119,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1120,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1121,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1122,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1123,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1124,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1125,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1126,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1127,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1128,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1129,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1130,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1131,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1132,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1133,拇,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1134,拇,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1135,拇,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1136,拇,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1137,拇,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1138,銝剜,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1139,銝剜,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1140,銝剜,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1141,銝剜,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1142,銝剜,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1143,,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1144,,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1145,,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1146,,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1147,,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,臺中榮總,es_22
1148,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1149,Donepezil Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1150,Donepezil Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_STEP,Rivastigmine,Step,臺中榮總,es_22
1151,Donepezil Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1152,Donepezil 5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1153,Donepezil Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1154,Donepezil Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1155,Donepezil Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1156,Donepezil Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1157,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1158,Rivastigmine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1159,Rivastigmine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_STEP,Rivastigmine,Step,臺中榮總,es_22
1160,Rivastigmine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1161,Rivastigmine 1.5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1162,Rivastigmine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1163,Rivastigmine Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1164,Rivastigmine 1.5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1165,Rivastigmine Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1166,Rivastigmine Treatment (箔葉璁桃蜇) (3),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1167,Rivastigmine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1168,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1169,Rivastigmine Patch Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1170,Rivastigmine Patch Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_STEP,Rivastigmine,Step,臺中榮總,es_22
1171,Rivastigmine Patch Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1172,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1173,Rivastigmine Patch Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1174,Rivastigmine Patch Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1175,Rivastigmine Patch Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1176,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1177,Galantamine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1178,Galantamine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_STEP,Rivastigmine,Step,臺中榮總,es_22
1179,Galantamine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1180,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1181,Galantamine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1182,Galantamine Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1183,Galantamine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1184,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1185,Memantine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1186,Memantine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_STEP,Rivastigmine,Step,臺中榮總,es_22
1187,Memantine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1188,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,Rivastigmine,Duration,臺中榮總,es_22
1189,Memantine Treatment (箔葉璁桃蜇) (1),Step,臺中榮總,es_22,STEP_STEP,Rivastigmine,Step,臺中榮總,es_22
1190,Memantine Treatment (箔葉璁桃蜇) (2),Step,臺中榮總,es_22,STEP_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1191,Memantine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1192,Memantine Treatment (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1193,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_TREATMENT,Rivastigmine,Treatment,臺中榮總,es_22
1194,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),Treatment,臺中榮總,es_22,DRUG_TREATMENT,Rivastigmine,drug,臺中榮總,es_22
1195,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),Step,臺中榮總,es_22,TREATMENT_DOSAGE,Rivastigmine,Dosage,臺中榮總,es_22
1196,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1197,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1198,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,Rivastigmine,Population,臺中榮總,es_22
1199,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1200,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1201,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1202,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1203,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1204,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1205,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1206,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1207,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1208,Donepezil,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1209,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1210,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1211,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1212,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1213,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1214,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1215,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1216,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1217,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1218,Rivastigmine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1219,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1220,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1221,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1222,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1223,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1224,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1225,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1226,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1227,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1228,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1229,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1230,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1231,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1232,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1233,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1234,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1235,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1236,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1237,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1238,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1239,Galantamine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1240,Memantine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1241,Memantine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1242,Memantine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1243,Memantine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1244,Memantine,drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,Rivastigmine,SideEffect,臺中榮總,es_22
1245,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1246,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1247,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1248,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1249,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1250,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1251,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1252,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1253,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1254,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1255,Alzheimer disease,disease,臺中榮總,es_22,DISEASES_THERAPY,Rivastigmine,Therapy,臺中榮總,es_22
1256,Reminiscence Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,THERAPY_EFFECTIVENESS,臺中榮總,es_22
1257,Cognitive Activities,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1258,Music Therapy Groups,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1259,Art Creation,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1260,Exercise Groups,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1261,Reality Orientation Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1262,Dance Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1263,Horticulture Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1264,Aromatherapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1265,Pet Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1266,Doll Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1267,Sensory Stimulation,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,Rivastigmine,Effectiveness,臺中榮總,es_22
1268,Donepezil,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1269,Donepezil,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1270,Donepezil,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1271,Donepezil,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1272,Donepezil,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1273,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1274,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1275,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1276,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1277,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1278,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1279,Rivastigmine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1280,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1281,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1282,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1283,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1284,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1285,Rivastigmine Patch,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1286,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1287,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1288,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1289,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1290,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1291,Galantamine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1292,Memantine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1293,Memantine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1294,Memantine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1295,Memantine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1296,Memantine,drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,Rivastigmine,Phenotypes,臺中榮總,es_22
1297,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1298,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1299,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1300,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1301,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1302,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1303,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1304,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1305,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Treatment,Alzheimer Society,es_2
1306,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1307,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1308,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1309,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1310,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1311,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1312,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1313,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1314,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1315,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1316,Early stage(GDS 2-5),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1317,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1318,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1319,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1320,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1321,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1322,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1323,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1324,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1325,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1326,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1327,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1328,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1329,Middle stage (GDS 4-6),Stage,Alzheimer Society,es_2,STAGE_PHENOTYPES,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1330,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1331,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1332,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1333,Late stage (GDS 7),Stage,Alzheimer Society,es_2,STAGE_TREATMENT,Rivastigmine,Phenotypes,Alzheimer Society,es_2
1334,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1335,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1336,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1337,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1338,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1339,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1340,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1341,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1342,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1343,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1344,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1345,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1346,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1347,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cocharne Library,es_6
1348,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cocharne Library,es_6
1349,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cocharne Library,es_6
1350,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cocharne Library,es_6
1351,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,IJN,es_15
1352,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,Rivastigmine,Evidence,Cocharne Library,es_7
1353,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1354,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Rivastigmine,drug,Japanese Society of Neurology,es_17
1355,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Rivastigmine,Dosage,Japanese Society of Neurology,es_17
1356,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Rivastigmine,Population,Japanese Society of Neurology,es_17
1357,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1358,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Rivastigmine,drug,Japanese Society of Neurology,es_17
1359,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Rivastigmine,Dosage,Japanese Society of Neurology,es_17
1360,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Rivastigmine,Population,Japanese Society of Neurology,es_17
1361,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1362,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Rivastigmine,drug,Japanese Society of Neurology,es_17
1363,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Rivastigmine,Dosage,Japanese Society of Neurology,es_17
1364,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Rivastigmine,Population,Japanese Society of Neurology,es_17
1365,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Rivastigmine,Treatment,Japanese Society of Neurology,es_17
1366,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Rivastigmine,drug,Japanese Society of Neurology,es_17
1367,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Rivastigmine Patch 9.5 mg/day,Dosage,Japanese Society of Neurology,es_17
1368,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Japanese Society of Neurology,es_17
1369,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17
1370,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Memantine,drug,Japanese Society of Neurology,es_17
1371,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Memantine 20 mg/day,Dosage,Japanese Society of Neurology,es_17
1372,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Japanese Society of Neurology,es_17
1373,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17
1374,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,Memantine,drug,Japanese Society of Neurology,es_17
1375,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Memantine 28 mg/day,Dosage,Japanese Society of Neurology,es_17
1376,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,Donepezil 5-10 mg/day,Dosage,Japanese Society of Neurology,es_17
1377,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Japanese Society of Neurology,es_17
1378,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_THERAPY,Exercise therapy,Therapy,Japanese Society of Neurology,es_17
1379,Alzheimer disease,disease,Japanese Society of Neurology,es_17,DISEASES_THERAPY,Music therapy,Therapy,Japanese Society of Neurology,es_17
1380,Exercise therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EVIDENCE_LEVEL,Low quality (Level C),Evidence,Cocharne Library,es_8
1381,Music therapy,Therapy,Ministry of Health Malaysia,es_18,THERAPY_EVIDENCE_LEVEL,Low quality (Level C),Evidence,Cocharne Library,es_9
1382,Exercise therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EFFECTIVENESS,attenuates worsening of physical function and activities of daily living,Effectiveness,Japanese Society of Neurology,es_17
1383,Music therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EFFECTIVENESS,"improving BPSD, including anxiety",Effectiveness,Japanese Society of Neurology,es_17
1384,(MCI) due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1385,(MCI) due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1386,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Suvorexant,Treatment,Alzheimer's Association,es_3
1387,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1388,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1389,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1390,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1391,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1392,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Suvorexant,Treatment,Alzheimer's Association,es_3
1393,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1394,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1395,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1396,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1397,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1398,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Donepezil Treatment (Alzheimer Society of B.C.),Treatment,Alzheimer's Association,es_3
1399,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Memantine Treatment (Alzheimer Society of B.C.),Treatment,Alzheimer's Association,es_3
1400,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1401,MCI due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,memory loss,Phenotypes,Alzheimer's Association,es_3
1402,MCI due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,cognitive ability loss,Phenotypes,Alzheimer's Association,es_3
1403,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Difficultly coming up with the right word or name.,Phenotypes,Alzheimer's Association,es_3
1404,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Difficultly remembering names when introduced to new people.,Phenotypes,Alzheimer's Association,es_3
1405,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Having difficulty performing tasks in social or work settings.,Phenotypes,Alzheimer's Association,es_3
1406,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Forgetting material that was just read.,Phenotypes,Alzheimer's Association,es_3
1407,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Losing or misplacing a valuable object.,Phenotypes,Alzheimer's Association,es_3
1408,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Experiencing increased trouble with planning or organizing.,Phenotypes,Alzheimer's Association,es_3
1409,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Being forgetful of events or personal history.,Phenotypes,Alzheimer's Association,es_3
1410,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",Phenotypes,Alzheimer's Association,es_3
1411,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",Phenotypes,Alzheimer's Association,es_3
1412,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Experiencing confusion about where they are or what day it is.,Phenotypes,Alzheimer's Association,es_3
1413,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Requiring help choosing proper clothing for the season or the occasion.,Phenotypes,Alzheimer's Association,es_3
1414,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Having trouble controlling their bladder and bowels.,Phenotypes,Alzheimer's Association,es_3
1415,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",Phenotypes,Alzheimer's Association,es_3
1416,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Showing an increased tendency to wander and become lost.,Phenotypes,Alzheimer's Association,es_3
1417,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",Phenotypes,Alzheimer's Association,es_3
1418,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Require around-the-clock assistance with daily personal care.,Phenotypes,Alzheimer's Association,es_3
1419,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Lose awareness of recent experiences as well as of their surroundings.,Phenotypes,Alzheimer's Association,es_3
1420,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",Phenotypes,Alzheimer's Association,es_3
1421,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,Have difficulty communicating.,Phenotypes,Alzheimer's Association,es_3
1422,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,"Become vulnerable to infections, especially pneumonia.",Phenotypes,Alzheimer's Association,es_3
1423,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1424,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Donanemab,drug,Alzheimer's Association,es_3
1425,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,MCI to Mild Alzheimer's Disease,Population,Alzheimer's Association,es_3
1426,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1427,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Lecanemab,drug,Alzheimer's Association,es_3
1428,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,MCI to Mild Alzheimer's Disease,Population,Alzheimer's Association,es_3
1429,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1430,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Donepezil,drug,Alzheimer's Association,es_3
1431,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Mild to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3
1432,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1433,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Rivastigmine,drug,Alzheimer's Association,es_3
1434,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3
1435,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1436,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Galantamine,drug,Alzheimer's Association,es_3
1437,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3
1438,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1439,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Memantine,drug,Alzheimer's Association,es_3
1440,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3
1441,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1442,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Memantine,drug,Alzheimer's Association,es_3
1443,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Donepezil,drug,Alzheimer's Association,es_3
1444,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3
1445,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1446,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Brexpiprazole,drug,Alzheimer's Association,es_3
1447,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Agitation associated with dementia due to Alzheimer's disease,Population,Alzheimer's Association,es_3
1448,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3
1449,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,Suvorexant,drug,Alzheimer's Association,es_3
1450,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Insomnia,Population,Alzheimer's Association,es_3
1451,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3
1452,Donanemab,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,ARIA,SideEffect,Alzheimer's Association,es_3
1453,Donanemab,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,headache,SideEffect,Alzheimer's Association,es_3
1454,Lecanemab,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Infusion-related reactions,SideEffect,Alzheimer's Association,es_3
1455,Lecanemab,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,ARIA,SideEffect,Alzheimer's Association,es_3
1456,Lecanemab,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,headache,SideEffect,Alzheimer's Association,es_3
1457,Donepezil,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Nausea,SideEffect,Alzheimer's Association,es_3
1458,Donepezil,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Vomiting,SideEffect,Alzheimer's Association,es_3
1459,Donepezil,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Loss of appetite,SideEffect,Alzheimer's Association,es_3
1460,Donepezil,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Muscle cramps,SideEffect,Alzheimer's Association,es_3
1461,Donepezil,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3
1462,Galantamine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Nausea,SideEffect,Alzheimer's Association,es_3
1463,Galantamine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Vomiting,SideEffect,Alzheimer's Association,es_3
1464,Galantamine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Loss of appetite,SideEffect,Alzheimer's Association,es_3
1465,Galantamine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3
1466,Rivastigmine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Nausea,SideEffect,Alzheimer's Association,es_3
1467,Rivastigmine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Vomiting,SideEffect,Alzheimer's Association,es_3
1468,Rivastigmine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Loss of appetite,SideEffect,Alzheimer's Association,es_3
1469,Rivastigmine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3
1470,Memantine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,headache,SideEffect,Alzheimer's Association,es_3
1471,Memantine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Constipation,SideEffect,Alzheimer's Association,es_3
1472,Memantine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Confusion,SideEffect,Alzheimer's Association,es_3
1473,Memantine,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Dizziness,SideEffect,Alzheimer's Association,es_3
1474,Brexpiprazole,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Weight gain,SideEffect,Alzheimer's Association,es_3
1475,Brexpiprazole,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Sleepiness,SideEffect,Alzheimer's Association,es_3
1476,Brexpiprazole,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Dizziness,SideEffect,Alzheimer's Association,es_3
1477,Brexpiprazole,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Common cold symptoms,SideEffect,Alzheimer's Association,es_3
1478,Brexpiprazole,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Restlessness or feeling like  need to move,SideEffect,Alzheimer's Association,es_3
1479,Suvorexant,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Impaired alertness and motor coordination,SideEffect,Alzheimer's Association,es_3
1480,Suvorexant,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Worsening of depression or suicidal thinking,SideEffect,Alzheimer's Association,es_3
1481,Suvorexant,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Complex sleep behaviors,SideEffect,Alzheimer's Association,es_3
1482,Suvorexant,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Sleep paralysis,SideEffect,Alzheimer's Association,es_3
1483,Suvorexant,drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,Compromised respiratory function,SideEffect,Alzheimer's Association,es_3
1484,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Maintain regular times for meals and for going to bed and getting up,Therapy,Alzheimer's Association,es_3
1485,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Seek morning sunlight exposure,Therapy,Alzheimer's Association,es_3
1486,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,"Encourage regular daily exercise, but no later than four hours before bedtime",Therapy,Alzheimer's Association,es_3
1487,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,"Avoid alcohol, caffeine and nicotine",Therapy,Alzheimer's Association,es_3
1488,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Treat any pain,Therapy,Alzheimer's Association,es_3
1489,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",Therapy,Alzheimer's Association,es_3
1490,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Make sure the bedroom temperature is comfortable,Therapy,Alzheimer's Association,es_3
1491,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Provide nightlights and security objects,Therapy,Alzheimer's Association,es_3
1492,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",Therapy,Alzheimer's Association,es_3
1493,Alzheimer disease,disease,Alzheimer's Association,es_3,DISEASES_THERAPY,Discourage watching television during periods of wakefulness,Therapy,Alzheimer's Association,es_3
1494,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4
1495,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4
1496,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4
1497,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Memory loss for recent events,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1498,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Difficulty learning new information,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1499,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Subtle language problems,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1500,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Significant memory loss,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1501,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Confusion in daily activities,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1502,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Behavioral changes,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1503,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Severe memory loss,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1504,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Complete dependence on others,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1505,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,Physical symptoms,Symptom,The Association of Scientific Medical Societies in Germany,es_4
1506,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1507,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1508,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1509,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1510,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1511,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1512,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1513,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1514,Donepezil Treatment (Demenzen),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,The Association of Scientific Medical Societies in Germany,es_4
1515,Rivastigmine Treatment (Demenzen),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,The Association of Scientific Medical Societies in Germany,es_4
1516,Galantamine Treatment (Demenzen),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,The Association of Scientific Medical Societies in Germany,es_4
1517,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,pubmed,es_13
1518,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1519,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4
1520,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,Donepezil 5mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4
1521,Donepezil 5mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4,DOSAGE_DURATION,1 month,Duration,The Association of Scientific Medical Societies in Germany,es_4
1522,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4
1523,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4
1524,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1525,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,Galantamine,drug,The Association of Scientific Medical Societies in Germany,es_4
1526,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,Galantamine 8mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4
1527,Galantamine 8mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4,DOSAGE_DURATION,1 month,Duration,The Association of Scientific Medical Societies in Germany,es_4
1528,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4
1529,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4
1530,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1531,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4
1532,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,Memantine 5mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4
1533,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DOSAGE_DURATION,Review every 6 months,Duration,The Association of Scientific Medical Societies in Germany,es_4
1534,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,significant effect on ADL function at 24 weeks,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4
1535,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,The Association of Scientific Medical Societies in Germany,es_4
1536,Alzheimer disease,disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4
1537,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,Rivastigmine,drug,The Association of Scientific Medical Societies in Germany,es_4
1538,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,Rivastigmine 3mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4
1539,Rivastigmine 3mg/day,Dosage,The Association of Scientific Medical Societies in Germany,es_4,DOSAGE_DURATION,2 weeks,Duration,The Association of Scientific Medical Societies in Germany,es_4
1540,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4
1541,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4
1542,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Nausea,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1543,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Vomiting,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1544,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1545,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1546,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1547,Donepezil,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Agitation,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1548,Rivastigmine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Gastrointestinal,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1549,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Agitation,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1550,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Hypertension,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1551,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Falls,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1552,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1553,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1554,Galantamine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Gastrointestinal,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1555,Galantamine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1556,Galantamine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4
1557,Memantine,drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_PHENOTYPES_CONTRAINDICATION,Severe renal impairment,Condition,The Association of Scientific Medical Societies in Germany,es_4
1558,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4
1559,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4
1560,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4
1561,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4
1562,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5
1563,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5
1564,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5
1565,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Memory loss for recent events,Symptom,Cognitive Decline Partnership Centre,es_5
1566,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Difficulty learning new information,Symptom,Cognitive Decline Partnership Centre,es_5
1567,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Subtle language problems,Symptom,Cognitive Decline Partnership Centre,es_5
1568,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Significant memory loss,Symptom,Cognitive Decline Partnership Centre,es_5
1569,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Confusion in daily activities,Symptom,Cognitive Decline Partnership Centre,es_5
1570,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Behavioral changes,Symptom,Cognitive Decline Partnership Centre,es_5
1571,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Severe memory loss,Symptom,Cognitive Decline Partnership Centre,es_5
1572,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Complete dependence on others,Symptom,Cognitive Decline Partnership Centre,es_5
1573,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,Physical symptoms,Symptom,Cognitive Decline Partnership Centre,es_5
1574,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1575,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1576,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1577,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1578,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1579,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1580,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1581,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1582,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,Low quality (Level C),Evidence,pubmed,es_21
1583,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,pubmed,es_21
1584,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,pubmed,es_21
1585,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,Moderate quality (Level B),Evidence,pubmed,es_21
1586,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1587,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,Donepezil,drug,Cognitive Decline Partnership Centre,es_5
1588,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_DOSAGE,Donepezil 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5
1589,Donepezil 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5,DOSAGE_DURATION,Review every 6 months,Duration,Cognitive Decline Partnership Centre,es_5
1590,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,Cognitive Decline Partnership Centre,es_5
1591,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Cognitive Decline Partnership Centre,es_5
1592,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1593,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,Galantamine,drug,Cognitive Decline Partnership Centre,es_5
1594,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_DOSAGE,Galantamine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5
1595,Galantamine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5,DOSAGE_DURATION,Review every 6 months,Duration,Cognitive Decline Partnership Centre,es_5
1596,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,Cognitive Decline Partnership Centre,es_5
1597,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Cognitive Decline Partnership Centre,es_5
1598,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1599,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,Memantine,drug,Cognitive Decline Partnership Centre,es_5
1600,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_DOSAGE,Memantine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5
1601,Memantine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5,DOSAGE_DURATION,Review every 6 months,Duration,Cognitive Decline Partnership Centre,es_5
1602,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EFFECTIVENESS,significant effect on ADL function at 24 weeks,Effectiveness,Cognitive Decline Partnership Centre,es_5
1603,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_POPULATION,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Cognitive Decline Partnership Centre,es_5
1604,Alzheimer disease,disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5
1605,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,Rivastigmine,drug,Cognitive Decline Partnership Centre,es_5
1606,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_DOSAGE,Rivastigmine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5
1607,Rivastigmine 5mg/day,Dosage,Cognitive Decline Partnership Centre,es_5,DOSAGE_DURATION,Review every 6 months,Duration,Cognitive Decline Partnership Centre,es_5
1608,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EFFECTIVENESS,small significant benefit on cognitive function and ADL,Effectiveness,Cognitive Decline Partnership Centre,es_5
1609,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_POPULATION,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Cognitive Decline Partnership Centre,es_5
1610,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Nausea,SideEffect,Cognitive Decline Partnership Centre,es_5
1611,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Vomiting,SideEffect,Cognitive Decline Partnership Centre,es_5
1612,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Diarrhea,SideEffect,Cognitive Decline Partnership Centre,es_5
1613,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5
1614,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5
1615,Donepezil,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Agitation,SideEffect,Cognitive Decline Partnership Centre,es_5
1616,Rivastigmine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Gastrointestinal,SideEffect,Cognitive Decline Partnership Centre,es_5
1617,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Agitation,SideEffect,Cognitive Decline Partnership Centre,es_5
1618,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Hypertension,SideEffect,Cognitive Decline Partnership Centre,es_5
1619,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Falls,SideEffect,Cognitive Decline Partnership Centre,es_5
1620,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5
1621,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5
1622,Galantamine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Gastrointestinal,SideEffect,Cognitive Decline Partnership Centre,es_5
1623,Galantamine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5
1624,Galantamine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5
1625,Memantine,drug,Cognitive Decline Partnership Centre,es_5,DRUG_PHENOTYPES_CONTRAINDICATION,Severe renal impairment,Condition,Cognitive Decline Partnership Centre,es_5
1626,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,Cognitive Decline Partnership Centre,es_5
1627,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,Cognitive Decline Partnership Centre,es_5
1628,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,Cognitive Decline Partnership Centre,es_5
1629,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,MONITORING_TREATMENT,Cognitive function (MMSE) every 6 months,Monitoring,Cognitive Decline Partnership Centre,es_5
